Biodexa Ltd, Subsidiary Of Biodexa Pharmaceuticals, Has Completed The Enrolment And Treatment Of Nine Pediatric Patients In The Ongoing Phase 1 Study Of MTX-110 In Newly Diagnosed Diffuse Midline Gliomas
Portfolio Pulse from Benzinga Newsdesk
Biodexa Ltd, a subsidiary of Biodexa Pharmaceuticals, has completed the enrolment and treatment of nine pediatric patients in the ongoing Phase 1 study of MTX-110 in newly diagnosed diffuse midline gliomas.
July 10, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa Pharmaceuticals' subsidiary, Biodexa Ltd, has completed a significant step in their Phase 1 study of MTX-110. This could potentially lead to positive outcomes for the company's drug development.
The completion of enrolment and treatment in a clinical trial is a significant milestone in drug development. This news indicates progress in Biodexa Pharmaceuticals' research and development efforts, which could potentially lead to positive outcomes for the company's drug MTX-110. This could positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100